Herpes zoster after COVID-19 vaccination, aspect of pain medicine: a retrospective, single-center study

Article information

Anesth Pain Med. 2023;18(1):57-64
Publication date (electronic) : 2023 January 16
doi : https://doi.org/10.17085/apm.22207
Department of Anesthesiology and Pain Medicine, Presbyterian Medical Center, Jeonju, Korea
Corresponding Author: Yu Yil Kim, M.D. Department of Anesthesiology and Pain Medicine, Presbyterian Medical Center, 365 Seowon-ro, Wansan-gu, Jeonju 54987, Korea Tel: 82-63-230-1594 Fax: 82-63-230-8919 Email: gangoaogi@naver.com
Received 2022 July 7; Revised 2022 September 29; Accepted 2022 October 16.



Herpes zoster (HZ) is one of the most common cutaneous adverse reactions associated with the coronavirus disease 2019 (COVID-19) vaccine and has been widely reported. This study aimed to evaluate HZ following COVID-19 vaccination from the viewpoint of pain management.


A retrospective study was conducted on 42 patients with HZ who visited the pain clinic between August 2021 and October 2021. Medical records were reviewed to compare pain severity, treatment methods, treatment duration, and incidence rate of postherpetic neuralgia (PHN) in patients who received COVID-19 vaccination within 6 weeks prior to developing symptoms compared with other patients with HZ.


Fourteen patients developed HZ within 6 weeks after vaccination and were significantly younger than the other HZ groups. There were no significant differences in the frequency of prodromal pain, location of pain, pain severity, treatment methods, treatment duration, or incidence of PHN compared with the other HZ groups.


COVID-19 vaccination-related HZ showed clinical features similar to those of the other HZ.


As coronavirus disease 2019 (COVID-19) was declared a global pandemic, vaccines are being developed rapidly, and mass vaccination has been performed in a short time. Vaccination is an efficient and safe way to resolve the COVID-19 pandemic; however, its adverse reactions have been continuously reported [1]. The most common adverse reactions associated with vaccines include injection site pain, fever, myalgia, headache, and fatigue, which can be treated easily in a short period [2,3]. However, rare, fatal postvaccination adverse reactions, such as myocarditis, thrombosis, and Guillain–Barré syndrome, have been reported [47].

Herpes zoster (HZ) is one of the adverse reactions of COVID-19 vaccination and is being continuously reported up to now [812]. HZ is caused by the reactivation of varicella-zoster virus (VZV), which remains latent in the dorsal root ganglia. It is characterized by severe pain along the area of the affected nerve with a unilateral skin lesion appearing around its cutaneous distribution [13,14]. HZ, which was reported in relation to COVID-19 vaccination, has been investigated from the perspective of dermatology regarding skin lesions [1517]. However, HZ may induce severe acute pain from nerve damage by the virus and postherpetic neuralgia (PHN), in which pain persists even after skin lesions improve [18]. PHN can affect patients’ daily lives and may cause depression, decreased quality of life, and social withdrawal [13,18]. In this regard, HZ should not only be considered a cutaneous adverse effect associated with COVID-19 vaccination. However, to the best of our knowledge, there have been no reports or studies of HZ from the perspective of pain medicine. Therefore, we conducted this study to compare the clinical features of HZ related to COVID-19 vaccination with those of other HZ from the perspective of pain medicine by retrospectively reviewing medical records.


This was a retrospective single-center study. This study was approved by the institutional review board of our hospital (no. 2021-11-046) and registered with the Clinical Research Information Service (no. KCT0006864). The present study was conducted according to the ethical principles for medical research of the Declaration of Helsinki 2013.

Patients who visited the pain clinic of our hospital from August 1, 2021, to October 31, 2021, were screened. During the study period, 475 patients visited the pain clinic, of whom 53 were diagnosed with HZ. Patients whose COVID-19 vaccination history was not clearly verified (n = 8), whose medical records were unreliable (n = 2), and who were referred to dermatologists because of chilblain-like lesions (n = 1) were excluded from this study (Fig. 1). Patients were divided into two groups based on 6-week (42-day) postvaccination [1]. Patients who were vaccination-naïve or had received a vaccine more than 6 weeks before were allocated to the control group (n = 28), and those who developed HZ within 6 weeks after vaccination were allocated to the COVID-19 vaccination-related HZ (CV-related HZ) group (n = 14).

Fig. 1.

Study flowchart. COVID-19: coronavirus disease 2019, CV-related HZ: coronavirus disease 2019 vaccination-related herpes zoster.

In the pain clinic of our hospital, we recognize the association between COVID-19 vaccination and HZ [11], and we have been documenting the history of COVID-19 vaccination in patients with HZ since approximately August 2021. The following data were collected from the patients’ medical records and analyzed: demographic information: (age and sex), COVID-19 vaccination-related information (vaccination status, types of vaccines, vaccination dose associated with HZ, and time from vaccination to development of HZ), and HZ-related information (time to development of prodromal pain and skin lesions, pain score, location of lesions, treatment methods, treatment duration, and development of PHN). PHN was defined as dermatomal pain persisting for > 90 days after the onset of acute HZ rash [18]. The time from vaccination to the development of HZ was defined as the time of onset of pain, not the time of onset of skin lesions. The vaccination date was not included in the calculation. An 11-point numerical rating scale was used to measure pain. In terms of treatment methods, the use of antiviral agents or anticonvulsants and application of nerve blocks were investigated.

Data are presented as mean (standard deviation) or median (interquartile range). The normality of the quantitative data was tested using the Shapiro–Wilk test, and data were analyzed using the independent t-test or Mann–Whitney U test. The chi-squared or Fisher’s exact test was used for categorical data. Statistical significance was set at P < 0.05. Statistical analyses were performed using the Statistical Package for the Social Sciences version 23 (IBM Corp., USA).


This study included 42 patients with HZ. Of the 32 patients who received COVID-19 vaccination, 14 developed HZ within 6 weeks after the vaccination. Ten patients did not receive any vaccination. The median age of the patients was 63.5 (34.5, 73.3) years, with 17 (40.5%) male and 25 (59.5%) female patients. Patients in the CV-related HZ group (52.0 [30.8, 62.3] years) were significantly younger than those in the control group (66.5 [54.3, 78.8] years) (P = 0.005). Prodromal pain was reported in 26 (61.9%) patients; thereafter, skin lesions developed after a median day of 3.0 (0.0, 4.0). The median pain scores were 3.0 (3.0, 4.0) and 4.0 (3.0, 4.0) in the CV-related HZ and control groups, respectively (P = 0.834). The most common locations of the lesion were the thoracic (64.3%) and cranial (14.3%) nerves. Antiviral agents (100%), anticonvulsants (87.2%), and nerve blocks (43.6%) were used. Moreover, 87.2% of the patients completely recovered within 12 weeks (Table 1). The other data did not show any statistical difference. In the CV-related HZ group, eight (57.1%) patients completely recovered within 4 weeks after symptom development. Although the difference was not statistically significant, five (12.8%) patients in the control group progressed to PHN (P = 0.092) (Fig. 2).

Demographic Data and Characteristics of Herpes Zoster-related Data

Fig. 2.

Recovery time for herpes zoster. The recovery rates within 8 weeks in the CV-related HZ and control groups are 85.7% and 68.0%, respectively. CV-related HZ: coronavirus disease 2019 vaccination-related herpes zoster.

In the CV-related HZ group, five patients received BNT162b2 (Pfizer), five received mRNA-1273 (Moderna), and four received ChAdOx1 nCov-19 (AstraZeneca). Ten patients developed symptoms after the second dose. Nine (64.3%) patients developed symptoms within 21 days of vaccination (Table 2).

Characteristics of Vaccination-related Herpes Zoster (n = 14)

The clinical information of patients with CV-related HZ and PHN is presented in Tables 3 and 4.

Characteristics of Patients with COVID-19 Vaccination-related Herpes Zoster and Herpes Zoster-associated Data

Characteristics of Patients with Postherpetic Neuralgia


In total, 42 patients with HZ were included in the present study, of whom 14 (33.3%) developed HZ within 6 weeks after COVID-19 vaccination. Except for age, demographic and HZ-related data did not show statistically significant differences between the groups. However, five patients in the control group developed PHN, whereas none of the patients in the CV-related HZ group progressed to PHN, but the difference was not statistically significant.

VZV, which remains latent in the ganglia, can be reactivated and replicated, inducing neuritis that directly damages the nerves. It is transported along the microtubules within the sensory axons in the affected nerve to infect the epithelial cells of the skin. This results in severe pain and skin lesions along the cutaneous distribution. Weakened VZV-specific T-cell-mediated immunity reactivates VZV. Its risk factors include immunosenescence, immunocompromised conditions due to disease, trauma, drug use, and psychological stress [14,19]. The outbreak of the COVID-19 pandemic and COVID-19 vaccination have been reported to be associated with the development of HZ [2023]. Its mechanism of action has been reported to be lymphopenia and T-cell dysfunction due to COVID-19 infection, and immunomodulation associated with COVID-19 vaccination weakens T-cell-mediated immunity, which inhibits VZV from being reactivated. However, its mechanism of action remains unclear [20,23].

Although HZ is accompanied by severe pain and is likely to progress to PHN, a neurological complication, most published cases of HZ after COVID-19 vaccination have been approached from the aspect of dermatology regarding skin lesions [1517]. Many studies have mentioned HZ in view of skin complications that occur after vaccination [24,25]. Even in studies that directly reported HZ, most described the association between HZ and vaccination or the mechanism [15,16]. In studies published from the aspect of dermatology, it was rare for the treatment and progress of HZ to be clearly described, as in the present study. In cases that clearly described the treatment for HZ and its progress, most treatment outcomes were highly good. Most patients improved with antiviral therapy, and there were no cases lasting > 6 weeks [165. However, five (35.7%) of the 14 patients with HZ required treatment for 6 weeks or longer (6–11 weeks) in the present study (Fig. 1). The reason that the treatment period of the present study was longer than those of previous studies is considered to be the additional treatment for persistent pain that occurs even after skin lesion improvement. We can deduce that such difference can be caused by the possibility of visiting the pain clinic rather than the dermatology department when patients mainly complained of severe pain. Generally, skin lesions of HZ completely recover within 2–4 weeks, and pain is known to last for an average of 45 days [26].

Antiviral therapy is important for the treatment of HZ. Antiviral therapy provided in the acute phase inhibits progression to PHN by inhibiting viral replication and reducing injury to nerve fibers and can also reduce the severity and duration of PHN. In addition, a decreased incidence of PHN was reported when antivirals were administered with gabapentin [27]. On the contrary, nerve blocks are effective in pain control in a short period of time, but their effects on PHN have not yet been clarified [19]. In the present study, all patients received antiviral therapy (100%) for the treatment of HZ, and anticonvulsants, such as gabapentin or pregabalin, were used in 87.2% of the patients. Moreover, 43.6% of the patients underwent nerve blocks. Nevertheless, five patients (male/female: 2/3; age, 66.0 [61.0, 77.5] years) in the control group developed PHN. Although the incidence of PHN in the two groups was not statistically significant, the reason for the absence of PHN in the CV-related HZ group can be deduced from the age of the two groups. Older age is the most potent risk factor for PHN because the nervous systems in the elderly may be less tolerant of the damage associated with HZ. In this study, it can be inferred that progression to PHN was absent in the CV-related HZ group because the patients were significantly younger. However, a large-scale additional study using such a large dataset is required to confirm this because this study has a small sample size.

The window in which the risk of HZ increases remains unclear. The risk window for HZ significantly varied, ranging from 21 days to 3 months, depending on the studies reported [1,22,23,28]. Barda et al. [1] set a follow-up period of 42 days after vaccination in a safety study on the COVID-19 vaccine. They believed that 42 days would be sufficient to identify medium-term adverse events without diluting the incidence of short-term adverse events. In their study, the risk of HZ was substantially higher in the vaccinated group than in the unvaccinated group (risk ratio, 1.43; 95% confidence interval [CI], 1.20–1.73; risk difference, 15.8 events per 100,000 persons; 95% CI, 8.2–24.2). Based on this, the present study used a 42-day risk window [1].

Of COVID-19 vaccines, an association between mRNA COVID-19 vaccination and HZ has been reported more frequently [7,9,16], but postvaccination HZ has been reported in almost all types of vaccines [8,10,29]. In the present study, five patients were in the Pfizer group, five in the Moderna group, and four in the AstraZeneca group. In Korea, there were approximately 75,287,995 vaccination cases by the end of October 2021, and there were 42,927,605 patients receiving Pfizer vaccine, 20,296,861 receiving AstraZeneca vaccine, 10,586,677 receiving Moderna vaccine, and 1,476,852 receiving Janssen vaccine. Since approximately 1.1 million cases in a specific occupational group received the Janssen vaccine in June 2021, the number of vaccination cases was small. Accordingly, there were no cases of Janssen vaccination in the present study.

The association between COVID-19 vaccination and HZ remains controversial. A meta-analysis by Chu et al. [30] reported that there was no evidence that COVID-19 vaccination increased the incidence of HZ (risk ratio, 1.06; 95% CI, 0.91–1.24). Patil et al. [28] also reported that there was no difference in the frequency of HZ before and 3 months after vaccination. In contrast, a case-control study by Alhasawi et al. [22] reported a significant association between COVID-19 vaccination and varicella zoster activation (odds ratio, 4.87; 95% CI, 2.40–9.89). Hertel et al. [23] also reported that the risk increased in the group who received vaccination, with a risk ratio of 1.802 (95% CI, 1.680–1.932). Temporal compatibility and biological plausibility should be confirmed to evaluate the causal association between HZ and COVID-19 vaccination in terms of adverse events following immunization. Future studies should investigate temporal compatibility and biological plausibility.

The present study has a strength in that it was conducted from the aspect of pain medicine, but its limitations are clear as it was a single-center, retrospective study that included a small sample size.Another limitation of this study is that the incidence of HZ associated with COVID-19 vaccination could not be evaluated. To overcome this limitation, a multicenter, prospective, large-scale study targeting a large population must be conducted in the future.

In the present study, patients with HZ associated with COVID-19 vaccination showed similar manifestations to general patients with HZ. They recovered after treatment with antiviral agents, anticonvulsants, and nerve blocks, and none of the patients developed PHN.





No potential conflict of interest relevant to this article was reported.


The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.


Conceptualization: Ji Hye Lee. Data curation: Hyun Joo Heo, Ji Hun Park, Hyung Gu Cho, Geonbo Kim. Writing - original draft: Yu Yil Kim. Writing - review & editing: Ji Hye Lee. Supervision: Yu Yil Kim. Validation: Hyun Joo Heo.


1. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2021;385:1078–90.
2. Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, et al. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open 2021;4e2140364.
3. Song JY, Cheong HJ, Kim SR, Lee SE, Kim SH, Noh JY, et al. Early safety monitoring of COVID-19 vaccines in healthcare workers. J Korean Med Sci 2021;36e110.
4. Patone M, Mei XW, Handunnetthi L, Dixon S, Zaccardi F, Shankar-Hari M, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. Nat Med 2022;28:410–22.
5. Garg RK, Paliwal VK. Spectrum of neurological complications following COVID-19 vaccination. Neurol Sci 2022;43:3–40.
6. Woo EJ, Mba-Jonas A, Dimova RB, Alimchandani M, Zinderman CE, Nair N. Association of receipt of the Ad26.COV2.S COVID-19 vaccine with presumptive Guillain-Barré syndrome, February-July 2021. JAMA 2021;326:1606–13.
7. Klein NP, Lewis N, Goddard K, Fireman B, Zerbo O, Hanson KE, et al. Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA 2021;326:1390–9.
8. Bostan E, Yalici-Armagan B. Herpes zoster following inactivated COVID-19 vaccine: a coexistence or coincidence? J Cosmet Dermatol 2021;20:1566–7.
9. Furer V, Zisman D, Kibari A, Rimar D, Paran Y, Elkayam O. Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series. Rheumatology (Oxford) 2021;60(SI):SI90–5.
10. Park JH, Lee JH, Oh JY, Heo HJ, Jung DW, Cho HG. Herpes zoster as a sequelae of various kinds of COVID-19 vaccination: a case series. Int J Pain 2021;12:19–23.
11. Psichogiou M, Samarkos M, Mikos N, Hatzakis A. Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel) 2021;9:572.
12. Gringeri M, Battini V, Cammarata G, Mosini G, Guarnieri G, Leoni C, et al. Herpes zoster and simplex reactivation following COVID-19 vaccination: new insights from a vaccine adverse event reporting system (VAERS) database analysis. Expert Rev Vaccines 2022;21:675–84.
13. van Oorschot D, Vroling H, Bunge E, Diaz-Decaro J, Curran D, Yawn B. A systematic literature review of herpes zoster incidence worldwide. Hum Vaccin Immunother 2021;17:1714–32.
14. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010;48(Suppl 1):S2–7.
15. Katsikas Triantafyllidis K, Giannos P, Mian IT, Kyrtsonis G, Kechagias KS. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines (Basel) 2021;9:1013.
16. Rodríguez-Jiménez P, Chicharro P, Cabrera LM, Seguí M, Morales-Caballero Á, Llamas-Velasco M, et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: report of 5 cases. JAAD Case Rep 2021;12:58–9.
17. Desai HD, Sharma K, Shah A, Patoliya J, Patil A, Hooshanginezhad Z, et al. Can SARS-CoV-2 vaccine increase the risk of reactivation of Varicella zoster? A systematic review. J Cosmet Dermatol 2021;20:3350–61.
18. Johnson RW, Rice AS. Clinical practice. Postherpetic neuralgia. N Engl J Med 2014;371:1526–33.
19. Tontodonati M, Ursini T, Polilli E, Vadini F, Di Masi F, Volpone D, et al. Post-herpetic neuralgia. Int J Gen Med 2012;5:861–71.
20. Tartari F, Spadotto A, Zengarini C, Zanoni R, Guglielmo A, Adorno A, et al. Herpes zoster in COVID-19-positive patients. Int J Dermatol 2020;59:1028–9.
21. Maia CMF, Marques NP, de Lucena EHG, de Rezende LF, Martelli DRB, Martelli-Júnior H. Increased number of herpes zoster cases in Brazil related to the COVID-19 pandemic. Int J Infect Dis 2021;104:732–3.
22. Alhasawi A, Kamel MI, Elmasry S, Kamel WA, Hassan A. Impact of COVID-19 vaccination on varicella zoster virus reactivation: a case control study. Microbiol Infect Dis 2021;5:1–6.
23. Hertel M, Heiland M, Nahles S, von Laffert M, Mura C, Bourne PE, et al. Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. J Eur Acad Dermatol Venereol 2022;36:1342–8.
24. Català A, Muñoz-Santos C, Galván-Casas C, Roncero Riesco M, Revilla Nebreda D, Solá-Truyols A, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 2022;186:142–52.
25. McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registry-based study of 414 cases. J Am Acad Dermatol 2021;85:46–55.
26. Drolet M, Brisson M, Levin MJ, Schmader KE, Oxman MN, Johnson RW, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain 2010;26:656–66.
27. Lapolla W, Digiorgio C, Haitz K, Magel G, Mendoza N, Grady J, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol 2011;147:901–7.
28. Patil SA, Dygert L, Galetta SL, Balcer LJ, Cohen EJ. Apparent lack of association of COVID-19 vaccination with herpes zoster. Am J Ophthalmol Case Rep 2022;26:101549.
29. Koumaki D, Krueger-Krasagakis SE, Papadakis M, Katoulis A, Koumaki V, Evangelou G, et al. Herpes zoster viral infection after AZD1222 and BNT162b2 coronavirus disease 2019 mRNA vaccines: a case series. J Eur Acad Dermatol Venereol 2022;36:e85–6.
30. Chu CW, Jiesisibieke ZL, Yang YP, Wu PC, Lin HL, Tung TH. Association of COVID-19 vaccination with herpes zoster: a systematic review and meta-analysis. Expert Rev Vaccines 2022;21:601–8.

Article information Continued

Fig. 1.

Study flowchart. COVID-19: coronavirus disease 2019, CV-related HZ: coronavirus disease 2019 vaccination-related herpes zoster.

Fig. 2.

Recovery time for herpes zoster. The recovery rates within 8 weeks in the CV-related HZ and control groups are 85.7% and 68.0%, respectively. CV-related HZ: coronavirus disease 2019 vaccination-related herpes zoster.

Table 1.

Demographic Data and Characteristics of Herpes Zoster-related Data

Variable CV-related HZ (n = 14) Control (n = 28) P value
Demographic data
 Age (yr) 52.0 (30.8, 62.3) 66.5 (54.3, 78.8) 0.005
 Sex, M/F 6 (42.9)/8 (57.1) 11 (39.3)/17 (60.7) 0.824
 Medical history
  Total 9 (64.3) 20 (71.4) 0.447
  Cardiovascular 3 (21.4) 12 (42.9)
  Endocrine 3 (21.4) 8 (28.6)
  Pulmonary 1 (7.1) 2 (7.1)
  Nephrotic 0 (0.0) 2 (7.1)
  Cerebrovascular 0 (0.0) 5 (17.9
  Allergy 3 (21.4) 3 (10.7)
  Malignant 0 (0.0) 4 (14.3)
Characteristics of herpes zoster
 Prodromal pain 9 (64.3) 17 (60.7) 0.822
 Interval between prodromal pain and rash (d) 3.0 (0.0, 4.0) 3.0 (0.0, 4.75) 0.661
 Pain score, NRS
  Initial pain 3.0 (3.0, 4.0) 4.0 (3.0, 4.0) 0.843
  Peak pain 4.0 (3.0, 4.3) 4.0 (3.3, 5.0) 0.535
  Cranial 2 (14.3) 4 (14.3) 0.689
  Cervical 2 (14.3) 2 (7.1) 0.407
  Thoracic 9 (64.3) 18 (64.3) 0.629
  Lumbar 1 (7.1) 1 (3.6) 0.561
  Sacral 0 (0.0) 3 (10.7) 0.285
Patients number 14 25*
  Antiviral agents 14 (100) 25 (100)
  Anticonvulsants 12 (85.7) 22 (88.0) 0.600
  Nerve block 6 (42.9) 11 (44.0) 0.945
 Recovery time (wk)
  1–4 8 (57.1) 10 (40.0) 0.303
  5–8 4 (28.6) 7 (28.0) 0.624
  8–12 2 (14.3) 3 (12.0) 0.600
  > 12 0 (0.0) 5 (20.0) 0.092
 Postherpetic neuralgia 0 (0.0) 5 (20.0) 0.092

Values are presented as median (1Q, 3Q) or number (%). CV-related HZ: coronavirus disease 2019 vaccination-related herpes zoster, NRS: numerical rating scale.


Three patients were excluded: one patient was transferred to another hospital, one was lost to follow-up, and one was transferred to the emergency room at the second visit due to a high fever.

Table 2.

Characteristics of Vaccination-related Herpes Zoster (n = 14)

Vaccine and dose 1st dose 2nd dose
 Pfizer 2 3
 Moderna 1 4
 AstraZeneca 1 3
Time of symptom onset after vaccination
 1 - 21 days 9 (64.3)
 22 - 42 days 5 (35.7)

Values are presented as number (%).

Table 3.

Characteristics of Patients with COVID-19 Vaccination-related Herpes Zoster and Herpes Zoster-associated Data

Variable Age (yr) Sex, M/F COVID-19 vaccination
Time interval of HZ onset after vaccination (d) Comorbidities
Types Dose
Patient 1 30 F Pfizer 1st 31 Food allergy
Patient 2 71 M AstraZeneca 2nd 1 Hypertension, type 2 diabetes, gastrectomy
Patient 3 63 F AstraZeneca 1st 1 Nontoxic goiter
Patient 4 57 F Moderna 2nd 28 None
Patient 5 21 F Pfizer 2nd 33 Atopic dermatitis, appendectomy
Patient 6 54 M Moderna 2nd 2 Atrial fibrillation, appendectomy
Patient 7 59 M Moderna 2nd 30 None
Patient 8 50 M Moderna 2nd 12 Asthma
Patient 9 31 M Pfizer 1st 6 Mite allergy
Patient 10 66 F AstraZeneca 2nd 33 Angina
Patient 11 62 F AstraZeneca 2nd 5 Gastrointestinal disease, hyperlipidemia
Patient 12 50 M Moderna 1st 10 Type 2 diabetes, hyperlipidemia
Patient 13 28 F Pfizer 2nd 14 None
Patient 14 32 F Pfizer 2nd 3 None
Herpes zoster-associated data
Variable Interval between prodromal pain and rash (d) Pain score, NRS (0–10)
Skin lesion severity Location HZ treatment
Initial Peak Antiviral agents Anticonvulsants Antidepressants Nerve blocks
Patient 1 4 3 3 Mild T1, T2 + +
Patient 2 0 3 3 Mild T10 + + + +
Patient 3 3 6 6 Mild L4, L5 + + + +
Patient 4 4 3 3 Mild T6, T7 + + + +
Patient 5 0 4 4 Severe T7, T8 + + + +
Patient 6 0 3 3 Mild T10 + + +
Patient 7 0 3 3 Mild V1 + +
Patient 8 0 4 4 Mild C2 + +
Patient 9 4 3 3 Mild V1 + + + +
Patient 10 4 4 4 Mild T10, T11 +
Patient 11 7 4 4 Mild T6, T8 + +
Patient 12 3 2 2 Mild T11 + +
Patient 13 4 5 5 Mild T5 + + +
Patient 14 2 3 3 Mild C3 +

HZ: herpes zoster, NRS: numerical rating scale, COVID-19: coronavirus disease 2019.

Table 4.

Characteristics of Patients with Postherpetic Neuralgia

Variable Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Age (yr) 73 66 58 82 64
Sex, M/F M F F F M
COVID-19 vaccination, yes/no Yes No No No No
(AstraZeneca 1st dose)
Time interval of HZ onset after vaccination (d)
Comorbidities Hypertension, asthma Osteoporosis Breast and thyroid cancers Diabetes, cerebral infarction, dementia Hypertension, diabetes
Interval between prodromal pain and rash (d) 5 0 0 0 7
Pain score, initial/peak/PHN pain, 3/4/2 5/5/2 4/4/3 3/4/2 4/5/4
NRS (0–10)
Skin lesion severity Severe Moderate Severe Severe Severe
Location C3, C4, Lt T3, T4, Lt T3, T4, Rt T4, T5, Lt S1, S2, Rt
HZ treatment
 Antiviral agents + + + + +
 Anticonvulsants + + + + +
 Antidepressants + + +
 Nerve blocks + + +

HZ: herpes zoster, PHN: postherpetic neuralgia, COVID-19: coronavirus disease 2019, NRS: numerical rating scale, Lt: left, Rt: right.